Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Mar 17, 2021 9:29am
133 Views
Post# 32815222

Getting pass the sticking point

Getting pass the sticking point
I have been waiting for a long time to see the company starting hard marketing of their drugs.
Egrifta was launched a head of it’s time as the drug has many therapeutic benefits which has been discovered as the science has been evolving.
The company projected compounded sale growth of 20 per cent annually, the question is how?
Well limited time promotional programs have been a very successful to get to point of sale regardless of nature of the goods or services.
This is exactly what is happening now with both drugs, as per Egrifta still having the stigma of a cosmetic drug it is important to create an incentive for patients to initiate the treatment and the results speak for themselves.
Trogarzo has a very high compliance therefore once on Trogarzo  patients stay put so to get pass the first hurdle starting patients on the drug is the main sticking point.

https://www.couponxoo.com/tesamorelin-coupon
<< Previous
Bullboard Posts
Next >>